Key Highlights
- Doug Godshall named Executive Chairman after leading Shockwave Medical and HeartWare International.
- Dr. Zhen Su joins the board, bringing expertise from Marengo Therapeutics and Merck KGaA.
- Galvanize’s INUMI Flex Endoscopic Needle gains FDA 510(k) clearance.
- Aliya PEF System targets solid tumors with innovative non-thermal ablation technology.
- Focus on clinical impact and growth in interventional oncology.
Source: PR Newswire
Notable Quotes
- “Over the last several years I have been impressed by the clinical impact Galvanize products are having on patients and look forward to this expanded role as Executive Chairman where I can work more closely with the team on the INUMI Flex launch and scaling the commercial business.” — Doug Godshall, Executive Chairman at Galvanize
- “Having spent almost three decades of my career studying tumor immunology and developing immune-oncology treatments, I am impressed that Galvanize is developing innovative medical devices with exciting clinical impacts for patients, especially for late-stage cancer patients.” — Dr. Zhen Su, CEO at Marengo Therapeutics
SoHC's Take
Galvanize’s strategic leadership appointments of Doug Godshall and Dr. Zhen Su mark a significant step in strengthening its position in the pulsed electric field (PEF) technology market. Godshall’s track record in leading medical technology companies to successful acquisitions and Dr. Su’s expertise in oncology and immunology enhance Galvanize’s capability to innovate and expand in the interventional oncology space. The FDA 510(k) clearance of the INUMI Flex Endoscopic Needle is a crucial milestone, promising advanced treatment options for patients with solid tumors. With these leadership enhancements, Galvanize is well-positioned to pioneer transformative medical technologies and drive substantial clinical advancements.
